Two doses of AstraZeneca and Pfizer vaccines have 92, 96% protection capability against delta variant hospitalisation

A real-world study conducted by Public Health England has found that two doses of AstraZeneca and Pfizer vaccines are highly effective against the delta variant (B.1.617.2) of corona virus in England.

The study conducted in 14,019 people infected with the delta variant (B.1.617.2) found that two doses of AstraZeneca and Pfizer vaccines protect patients from taking hospitalisations. Of the 14,019 people infected with the delta variant, only 166 were admitted to hospitals. The study was undertaken between April 12 and June 4.

while full vaccination of AstraZeneca provides 92% protection against hospitalization, it was found that Pfizer is 96% effective in keeping patients away from hospitals. The results have been posted as a preprint. Preprints are yet to be peer-reviewed.

Public Health England had earlier found that despite modest reductions, vaccines remain effective against the delta variant. It found that in the case of the delta variant, full vaccination offered good protection against symptomatic disease. Vaccine effectiveness against symptomatic disease was 67% in the case of AstraZeneca and 88% with Pfizer, The Hindu reported.

Effectiveness against hospitalization was high even with one dose of AstraZeneca and Pfizer vaccine. In the case of delta variant, one dose of AstraZeneca vaccine offered 71% protection against hospitalization, while two doses offered 92% protection. In the case of Pfizer vaccine, the protection against hospitalization was 94% after one dose and 96% after two doses, the report said.

The Delta variant of the coronavirus is estimated to be 40 percent more transmissible than the Alpha variant that caused the last wave of infections in the UK.